Mucin layer of cornea (null)

The **mucin layer of the cornea** is not a single molecular target but rather refers to the innermost component of the tear film that coats the ocular surface. This hydrated gel-like structure is primarily composed of high-molecular-weight glycoproteins called **mucins**, which are produced by conjunctival goblet cells and epithelial cells on both the cornea and conjunctiva. The major gel-forming secreted mucin in this context is **MUC5AC**, while membrane-associated mucins such as **MUC1** and **MUC4** form part of the glycocalyx on epithelial microprojections (microvilli/microplicae)[1][3][4][5][7]. The main functions of this layer include maintaining wettability for even tear distribution, providing lubrication to reduce friction during blinking, forming a physical barrier against pathogens and debris, supporting immune defense at the ocular surface, and facilitating nutrient/gas exchange critical for avascular tissues like the cornea[1][3][4][5]. Deficiency or dysfunction in this protective barrier contributes significantly to dry eye disease and other ocular surface disorders. While drugs such as diquafosol (a P2Y2 receptor agonist) and rebamipide can stimulate increased production or secretion of these protective mucins—thus improving symptoms in dry eye patients—the "mucin layer" itself is not considered a direct therapeutic target like an enzyme or receptor would be. Instead, it represents an essential structural/functional component maintained by multiple underlying molecular targets (notably specific mucins such as MUC5AC)[7]. Because "mucin layer of cornea" does not refer to a discrete molecule or canonical drug target but rather to a functional tissue compartment composed mainly of various types/subtypes of mucins with distinct roles, it should be flagged as an incorrect entry if used where only individual molecules/receptors are appropriate.

Other names

Mucin layerCorneal mucin layerOcular surface mucin layerTear film mucin layer

Stimulation of mucin secretion from conjunctival goblet cells (e.g., via P2Y2 receptor agonists like diquafosol)